Poly(adp Ribose) Polymerase - Toxicology

Relevant Publications

Analysis of Apoptosis by Thyroid Hormone Induction.

Issue Release: 2025

Genetic Risk Loci and Familial Associations in Migraine: A Genome-Wide Association Study in the Han Chinese Population of Taiwan.

Issue Release: 2024

Financial toxicity of withdrawn poly (ADP-ribose) polymerase inhibitor indications for ovarian cancer.

Issue Release: 2024

Cancer therapeutic potential of hovetrichoside C from Jatropha podagrica on apoptosis of MDA-MB-231 human breast cancer cells.

Issue Release: 2024

Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship.

Issue Release: 2024

Poly (ADP-ribose) polymerase 1 promotes HuR/ELAVL1 cytoplasmic localization and inflammatory gene expression by regulating p38 MAPK activity.

Issue Release: 2024

Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development.

Issue Release: 2024

Clonorchis sinensis aggravated liver fibrosis by activating PARP-1 signaling to induce parthanatos via DNA damage.

Issue Release: 2024

Oncometabolite 2-hydroxyglutarate suppresses basal protein levels of DNA polymerase beta that enhances alkylating agent and PARG inhibition induced cytotoxicity.

Issue Release: 2024

N-desmethyldauricine from Menispermum dauricum DC suppresses triple-negative breast cancer growth in 2D and 3D models by downregulating the NF-κB signaling pathway.

Issue Release: 2024

The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.

Issue Release: 2024

DNA damage targeted therapy for advanced breast cancer.

Issue Release: 2024

Age Is a Risk Factor for Olaparib Dose Modification and Discontinuation in Patients With Ovarian Cancer.

Issue Release: 2024

Donafenib inhibits PARP1 expression and induces DNA damage, in combination with PARP1 inhibitors promotes apoptosis in liver cancer cells.

Issue Release: 2024

Epigenetic and Genomic Hallmarks of PARP-Inhibitor Resistance in Ovarian Cancer Patients.

Issue Release: 2024

Transcriptional regulation mechanism of PARP1 and its application in disease treatment.

Issue Release: 2024

Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer.

Issue Release: 2024

Synergistic Effects of Glutamine Deprivation and Metformin in Acute Myeloid Leukemia.

Issue Release: 2024

NAD metabolism and heart failure: Mechanisms and therapeutic potentials.

Issue Release: 2024

Piperine enhances doxorubicin sensitivity in triple-negative breast cancer by targeting the PI3K/Akt/mTOR pathway and cancer stem cells.

Issue Release: 2024

When Are Blood Transfusions Necessary in Toxicology?

Can Cardiomyocyte Apoptosis Be Prevented or Mitigated?

What are Some Examples of Immunosuppressive Agents?

Why is Exposure Assessment Important?

What is L-carnitine?

What Role Do ULs Play in Public Health?

How is Iron Deficiency Diagnosed?

What Can CVS Reveal About Toxic Exposure?

How Is Carcinogenic Risk Assessed?

How is Malondialdehyde Measured?

Partnered Content Networks

Relevant Topics